The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
.
Advised TherapeuticsMD, Inc., an innovative, leading women’s healthcare company on definitive agreements to license its products to Mayne Pharma
Advising the management and majority physician owners of GI Alliance, the largest gastroenterology practice in the United States, on its recapitalization and buyout of minority partner, Waud Capital
Advised Airtower Networks on its strategic growth capital raise from DIF Capital Partners
Advised Fusion Connect, Inc., a leading service provider of cloud communications and secure network solutions with a focus on serving mid-market and enterprise businesses on its comprehensive balance sheet recapitalization
Advised Acacia Pharma Group plc, a US headquartered commercial stage biopharmaceutical company incorporated in England and listed in Belgium, on its placing of 10m new ordinary shares at a price of €2.70 per share
Advising US Acute Care Solutions, the largest majority physician-owned emergency medicine practice in the United States, on its recapitalization and buyout of minority partner, Welsh Carson
Advised Ad Hoc Group of First Lien Term Loan Lenders on Akorn’s in-court recapitalization
Advised the Ad Hoc Group of First Lien Lenders on the Chapter 11 restructuring of Skillsoft Limited, a leading provider of e-learning and performance support solutions globally
Advised Ad Hoc Group of First Lien Term Loan B Lenders on the restructuring of 4L Holdings Corporation
Advised Wave Computing, a leading artificial intelligence solutions company developing proprietary dataflow-based architecture systems, on its successful $86mm Series E financing
Advised an Ad Hoc Group of Cross-over Debtholders on Concordia International’s cross-border Canadian restructuring and recapitalization, including a US$586.5mm common equity private placement, the equitization of ~US$1.7bn of unsecured debt and the partial paydown and exchange of ~US$2.2bn of secured debt
Advised The Bank of New York Mellon in its role as the Indenture Trustee to selected First Lien Notes throughout Avaya’s Chapter 11 proceedings
Advised Hirslanden Private Hospital Group, Switzerland's largest private hospital group and a wholly-owned subsidiary of Mediclinic International Plc, on the refinancing of its CHF 2.0 billion senior secured bank debt
Advised the Ad Hoc Group of Senior Secured Noteholders in connection with the restructuring of Goodman Networks.
Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the US rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.
Advised Airopack Technology Group, developer of a revolutionary all-plastic dispenser, on a €120 million debt and equity investment from funds managed by affiliates of Apollo Global Management, and the concurrently announced proposed acquisition of the 50% stake it does not already own in Airolux AG, its joint venture with Resilux NV
Advised the Special Committee of the Board of Directors of TNS, Inc., a leading global provider of data communications and interoperability solutions, on its sale to Siris Capital Group, a private equity firm focused on complex, control equity investments in the telecom, technology and technology-enabled business service sectors
Advised Mediclinic International, South Africa’s second largest and Switzerland’s largest provider of private hospital services, on the restructuring of its entire balance sheet, including $2.2 billion debt refinancing in Switzerland and a $0.6 billion rights issue in South Africa
Advised ISTA Pharmaceuticals, an ophthalmic pharmaceutical company, on its defense against an unsolicited offer from Valeant Pharmaceuticals and on its review of strategic alternatives
Advised Cabot Microelectronics Corporation on its new capital management initiative, including a leveraged recapitalization via a special dividend
Advised the Independent Director Committee of Alcon, Inc., an ophthalmic pharmaceutical company, on the sale of Alcon’s outstanding publicly held interest to Novartis AG, a global pharmaceutical company
Advised BearingPoint, Inc. on the sale of substantially all of its assets, pursuant to a Section 363 process